Engineered exosomes for improving wound healing
IL330648APending Publication Date: 2026-09-01EONVELAB CO LTD
View PDF 0 Cites -1 Cited by
Patent Information
- Application Number
- IL330648
- Authority / Receiving Office
- IL · IL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-15
- Filing Date
- 2025-01-14
- Publication Date
- 2026-09-01
AI Technical Summary
Technical Problem
Chronic wounds, such as those in diabetic patients, exhibit uncoordinated and prolonged healing processes, leading to increased infection risk and significant medical costs, with current treatments being unsatisfactory and invasive.
Method used
Engineered exosomes are developed with EGF, NGF, and PDGF-BB polypeptides anchored on their membrane via CD63 domains, exposing these growth factors on the surface to promote wound healing.
Benefits of technology
The engineered exosomes enhance wound healing by improving fibroblast proliferation and migration, accelerating wound closure, and reducing healing time, particularly effective in diabetic foot ulcers.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000043_0000 
Figure 00000043_0001 
Figure 00000043_0002
Abstract
Disclosed is an engineered exosome, comprising (a) an EGF polypeptide, fused to a first anchoring polypeptide, (b) a NGF polypeptide, fused to a second anchoring polypeptide, and (c) a PDGF-BB polypeptide, fused to a third anchoring polypeptide, wherein (a), (b) and (c) are anchored on a membrane of the exosome via the first, second and third anchoring polypeptide, respectively, and wherein the EGF polypeptide, the NGF polypeptide and the PDGF-BB polypeptide are exposed on an outer surface of the membrane of the exosome. Also disclosed are compositions, nucleic acid constructs, and uses of the exosome for wound healing.
Need to check novelty before this filing date? Find Prior Art